2024
Ulcerative Colitis Patients Are at Increased Risk for Adverse Events Following Total Hip Arthroplasty
Oghenesume O, Gouzoulis M, Ratnasamy P, Dhodapkar M, Grauer J, Rubin L. Ulcerative Colitis Patients Are at Increased Risk for Adverse Events Following Total Hip Arthroplasty. The Journal Of Arthroplasty 2024, 40: 1397-1403.e1. PMID: 39515400, DOI: 10.1016/j.arth.2024.10.134.Peer-Reviewed Original ResearchPostoperative adverse eventsAdverse eventsClasses of medicationsElixhauser Comorbidity IndexUlcerative colitisPatient ageTotal hip arthroplastyTotal hip arthroplasty patientsFive-year survivalUlcerative colitis patientsArthroplasty patientsPatient's medication regimenHip arthroplasty patientsDisease ulcerative colitisUC patientsColitis patientsComorbidity indexCorticosteroidsPerioperative periodIncreased riskHip arthroplastyPatientsMedication regimenDisease processMatched groupSex Differences in Hypertension and Its Management Throughout Life
Yeo W, Abraham R, Surapaneni A, Schlosser P, Ballew S, Ozkan B, Flaherty C, Yu B, Bonventre J, Parikh C, Kimmel P, Vasan R, Coresh J, Grams M. Sex Differences in Hypertension and Its Management Throughout Life. Hypertension 2024, 81: 2263-2274. PMID: 39229711, PMCID: PMC11483212, DOI: 10.1161/hypertensionaha.124.22980.Peer-Reviewed Original ResearchPrevalence of hypertensionUncontrolled hypertensionChronic kidney disease progressionPrevalence of uncontrolled hypertensionKidney disease progressionBody mass indexClasses of medicationsSex differencesEstimate sex differencesCoronary heart diseaseHeart failureMass indexAntihypertensive medicationsDisease progressionStudy visitsAtherosclerosis RiskHypertensionHigh riskHypertensive individualsHeart diseaseLife courseCommunity studiesPrevalenceMedicationPatterns of Psychiatric Medication Prescriptions for Veterans in Treatment Courts and Other Specialty Courts
Tsai J, Christian N, Szymkowiak D. Patterns of Psychiatric Medication Prescriptions for Veterans in Treatment Courts and Other Specialty Courts. Journal Of Psychiatric Practice 2024, 30: 119-129. PMID: 38526399, DOI: 10.1097/pra.0000000000000769.Peer-Reviewed Original ResearchConceptsCriminal justice-involvedVeterans Treatment CourtsSubstance use disordersPsychiatric medicationsPrescribed psychiatric medicationsTreatment courtsPsychiatric medication prescriptionSpecialty courtsClasses of psychiatric medicationsService-connected disability ratingVA health care servicesBehavioral health issuesJustice-involvedPsychiatric diagnosisUse disorderCourtPsychiatric prescribingPsychiatric prescriptionsClasses of medicationsVeteransService engagementMedication prescriptionsDisordersMedicationHealth care servicesPharmacological management of gambling disorder: an update of the literature
Mestre-Bach G, Potenza M. Pharmacological management of gambling disorder: an update of the literature. Expert Review Of Neurotherapeutics 2024, 24: 391-407. PMID: 38357896, DOI: 10.1080/14737175.2024.2316833.Peer-Reviewed Original ResearchGambling disorderCo-occurring disordersSerotonin reuptake inhibitorsPlacebo response ratesOpioid receptor antagonistMental health conditionsGlutamatergic agentsNeurobiological correlatesGambling subtypesMood stabilizersReuptake inhibitorsClasses of medicationsPharmacological treatmentBetting behaviorGamblingTreatment responsePharmacological interventionsDisordersPharmacological managementMedicationTreatment optionsNarrative reviewLongitudinal informationResponse rateNalmefene
2023
A randomized clinical trial assessing the effect of automated medication-targeted alerts on acute kidney injury outcomes
Wilson F, Yamamoto Y, Martin M, Coronel-Moreno C, Li F, Cheng C, Aklilu A, Ghazi L, Greenberg J, Latham S, Melchinger H, Mansour S, Moledina D, Parikh C, Partridge C, Testani J, Ugwuowo U. A randomized clinical trial assessing the effect of automated medication-targeted alerts on acute kidney injury outcomes. Nature Communications 2023, 14: 2826. PMID: 37198160, PMCID: PMC10192367, DOI: 10.1038/s41467-023-38532-3.Peer-Reviewed Original ResearchConceptsAcute kidney injuryUsual care groupKidney injuryCare groupAcute Kidney Injury OutcomesAlert groupNon-steroidal anti-inflammatory drugsComposite of progressionHours of randomizationMedications of interestAldosterone system inhibitorsClasses of medicationsProton pump inhibitorsRandomized clinical trialsAnti-inflammatory drugsClinical decision support systemNephrotoxic medicationsHospitalized adultsDiscontinuation ratesCertain medicationsPrimary outcomeSubstantial morbiditySystem inhibitorsPump inhibitorsParallel groupAssociation between statin exposure and short-term mortality in patients with high-grade acute-on-chronic liver failure
Chapin S, Kaplan D, Taddei T, Mahmud N. Association between statin exposure and short-term mortality in patients with high-grade acute-on-chronic liver failure. JHEP Reports 2023, 5: 100740. PMID: 37215188, PMCID: PMC10193237, DOI: 10.1016/j.jhepr.2023.100740.Peer-Reviewed Original ResearchChronic liver failureShort-term mortalityRetrospective cohort studyStatin exposureLiver failureStatin useCohort studyLogistic regression modelsLower oddsHigh short-term mortalityVeterans Health Administration patientsDose exposureMultivariable logistic regression modelClasses of medicationsFuture prospective studiesVeterans Health AdministrationDose-dependent reductionPotential beneficial effectsStatin therapyTerm mortalityAnalytic cohortRegression modelsProspective studyReduced oddsACLF
2022
Ketones: the double-edged sword of SGLT2 inhibitors?
Lupsa BC, Kibbey RG, Inzucchi SE. Ketones: the double-edged sword of SGLT2 inhibitors? Diabetologia 2022, 66: 23-32. PMID: 36255460, DOI: 10.1007/s00125-022-05815-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSGLT2 inhibitorsDrug categoriesSodium-glucose cotransporter 2 inhibitorsCardio-renal benefitsNormal blood glucose concentrationsCotransporter 2 inhibitorsClasses of medicationsAnti-inflammatory effectsSerious adverse effectsType 1 diabetesBlood glucose levelsBlood glucose concentrationKidney outcomesRare complicationBlood pressureSGLT2 inhibitionGlucose levelsKetone levelsBody weightType 2Ketone bodiesAdverse effectsGlucose concentrationInhibitorsEdged swordPreoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement
Sahai SK, Balonov K, Bentov N, Bierle DMM, Browning LM, Cummings KC, Dougan BM, Maxwell M, Merli GJ, Oprea AD, Sweitzer B, Mauck KF, Urman RD. Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. Mayo Clinic Proceedings 2022, 97: 1734-1751. PMID: 36058586, DOI: 10.1016/j.mayocp.2022.03.039.Peer-Reviewed Original ResearchConceptsCardiovascular medicationsPerioperative assessmentAntiarrhythmic agentsReceptor antagonistAngiotensin receptor neprilysin inhibitorQuality Improvement (SPAQI) Consensus StatementAngiotensin II receptor blockersClass I antiarrhythmic agentsClass III antiarrhythmic agentII receptor blockersClasses of medicationsEndothelin receptor antagonistsPotassium-sparing diureticsCalcium channel blockersΒ-adrenoceptor blockersAdrenergic receptor antagonistPhosphodiesterase-5 inhibitorsEvidence-based recommendationsSodium channel blockersPotassium channel openersSympatholytic medicationsReceptor blockersPerioperative managementHeart failureLoop diuretics
2021
A Review of Phenobarbital for Alcohol Withdrawal Syndrome
Saadatmand H, Ho P. A Review of Phenobarbital for Alcohol Withdrawal Syndrome. Current Psychopharmacologye 2021, 10: 197-207. DOI: 10.2174/2211556010666210810094103.Peer-Reviewed Original ResearchAlcohol withdrawal syndromeAlcohol withdrawalIntensive care unitWithdrawal syndromeEmergency departmentCare unitIntensive care admission rateTrauma surgery serviceClasses of medicationsRetrospective cohort trialGeneral medical unitCommon clinical problemDose of phenobarbitalAlcohol use disorderSerious health problemCohort trialProspective randomizedClinical outcomesSurgery serviceCochrane DatabaseRetrospective trialsAdmission ratesInpatient settingOvid MEDLINESuperior efficacySACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation
Kaplan D, Mehta R, Garcia-Tsao G, Albrecht J, Aytaman A, Baffy G, Bajaj J, Hernaez R, Hunt K, Ioannou G, Johnson K, Kanwal F, Lee T, Monto A, Pandya P, Schaubel D, Taddei T. SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. Contemporary Clinical Trials 2021, 104: 106367. PMID: 33771685, PMCID: PMC8422958, DOI: 10.1016/j.cct.2021.106367.Peer-Reviewed Original ResearchConceptsHepatic decompensationPortal hypertensionEvents of decompensationHepatic decompensation eventsLiver-related deathSignificant portal hypertensionAcceptable safety profileProspective human studiesRole of statinsChronic liver diseaseClasses of medicationsPatient-reported outcomesDevelopment of decompensationEffect of simvastatinVA Medical CenterCompensated cirrhosisDecompensation eventsStatin therapyVariceal hemorrhageCirrhotic patientsStandard therapyVascular reactivityExert pleiotropic effectsLiver diseaseRetrospective studyBrain Structure and Function of Chronic Low Back Pain Patients on Long-Term Opioid Analgesic Treatment: A Preliminary Study
Murray K, Lin Y, Makary MM, Whang PG, Geha P. Brain Structure and Function of Chronic Low Back Pain Patients on Long-Term Opioid Analgesic Treatment: A Preliminary Study. Molecular Pain 2021, 17: 1744806921990938. PMID: 33567986, PMCID: PMC7883154, DOI: 10.1177/1744806921990938.Peer-Reviewed Original ResearchConceptsChronic low back painOpioid analgesicsCLBP patientsPain patientsChronic low back pain patientsLow back pain patientsBrain structuresOpioid analgesic treatmentBack pain patientsClasses of medicationsChronic pain patientsLow back painLong-term riskAltered brain structureSub-cortical areasOverall significant decreaseEvidence of misuseAnalgesic treatmentChronic treatmentBack painFunctional brain imagingLimbic areasUnmedicated patientsHealthy controlsNucleus accumbens
2020
Spinal cord stimulation and psychotropic medication use: Missing piece to the puzzle?
Hwang BY, Negoita S, Duy PQ, Anderson WS. Spinal cord stimulation and psychotropic medication use: Missing piece to the puzzle? Journal Of Clinical Neuroscience 2020, 81: 158-160. PMID: 33222907, PMCID: PMC9586422, DOI: 10.1016/j.jocn.2020.09.038.Peer-Reviewed Original ResearchConceptsPsychotropic medicationsSpinal cord stimulator therapyLow explantation rateTimes less likelihoodClasses of medicationsChronic pain managementChronic pain patientsPsychotropic medication useSpinal cord stimulationMajority of casesMedication usePain managementPain patientsDaily dosageTreatment failureCord stimulationDevice explantationRetrospective studySCS patientsExplantation ratePsychotropic useTreatment successMedication statusMedicationsModulatory effects
2019
Beta-Blockers for Migraine Prevention: a Review Article
Danesh A, Gottschalk PCH. Beta-Blockers for Migraine Prevention: a Review Article. Current Treatment Options In Neurology 2019, 21: 20. PMID: 30903383, DOI: 10.1007/s11940-019-0556-3.Peer-Reviewed Original ResearchMigraine prophylaxisMechanism of actionFavorable side effect profileBeta-blocker useCommon prophylactic agentsGroup of medicationsRecent FindingsNew evidenceClasses of medicationsSide effect profileSignificant clinical differencesMigraine preventionBeta blockersEffect profileClinical differencesProphylactic agentProphylaxisNumerous trialsRecent evidenceMedicationsPrevious reportsDosesRelative benefitsExtensive evidenceReview articleOptimum doses
2018
The Use of Stimulant Augmentation of Second Generation Antipsychotics in the Management of Negative Symptoms of Schizophrenia: A Case Report
Azizi H, Zeng Y, Kallikkadan J, Kahn A, Olayinka O, Popoola O, Khan T, Rimawi D, Malik A, Williams S, Langdon S, Obegolu C, Nuthalapati D, Alzear R, Kalbouneh H, Mahbub A, Ojimba C, Oyelakin A, Kodjo K, Ferdous Saad A, Jegede O, Jolayemi A. The Use of Stimulant Augmentation of Second Generation Antipsychotics in the Management of Negative Symptoms of Schizophrenia: A Case Report. International Journal Of Innovative Research In Medical Science 2018, 3 DOI: 10.23958/ijirms/vol03-i08/08.Peer-Reviewed Original ResearchNegative symptomsMesocortical pathwayStimulant medicationSymptom subscalesTwo-point reductionClasses of medicationsSecond-generation antipsychoticsPositive symptom subscaleThree-week trialNegative symptom subscaleAntipsychotic therapyNegative syndrome scoreGeneration antipsychoticsCase reportSyndrome scoreDopamine activityMedicationsSymptomsSchizophreniaThree-week periodScoresPotential benefitsSubscalesChapter 22 Current Status of Medical Therapy of Thoracic Aortic Aneurysm and Dissection
Percy A, Mukherjee S, Ziganshin B, Elefteriades J. Chapter 22 Current Status of Medical Therapy of Thoracic Aortic Aneurysm and Dissection. 2018, 235-249. DOI: 10.1016/b978-0-12-809979-7.00022-5.Peer-Reviewed Original ResearchThoracic aortic aneurysmAortic aneurysmMost thoracic aortic aneurysmsAngiotensin receptor blockersClasses of medicationsAortic aneurysm developmentRelevant clinical endpointsAortic aneurysm expansionAsymptomatic patientsLifestyle modificationReceptor blockersMedical therapySurgical repairAortic catastropheClinical evidencePathophysiologic pathwaysSurgical interventionPathophysiologic basisTreatment modalitiesAneurysm expansionClinical endpointsClinical trialsCurrent guidelinesAneurysm formationClinical studies
2017
Discontinuing a non-steroidal anti-inflammatory drug (NSAID) in patients with knee osteoarthritis: Design and protocol of a placebo-controlled, noninferiority, randomized withdrawal trial
Goulet JL, Buta E, Brennan M, Heapy A, Fraenkel L. Discontinuing a non-steroidal anti-inflammatory drug (NSAID) in patients with knee osteoarthritis: Design and protocol of a placebo-controlled, noninferiority, randomized withdrawal trial. Contemporary Clinical Trials 2017, 65: 1-7. PMID: 29198731, DOI: 10.1016/j.cct.2017.11.020.Peer-Reviewed Original ResearchMeSH KeywordsAcetaminophenAdultAge FactorsAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalDisability EvaluationDouble-Blind MethodEquivalence Trials as TopicFemaleHumansMaleMeloxicamMiddle AgedOsteoarthritis, KneePain MeasurementPatient Education as TopicResearch DesignSeverity of Illness IndexSex FactorsSocial SupportYoung AdultConceptsNon-steroidal anti-inflammatory drugsUse of NSAIDsOA knee painKnee painKnee osteoarthritisAnti-inflammatory drugsWithdrawal trialCurrent non-steroidal anti-inflammatory drugsKnee OA painPainful knee osteoarthritisClasses of medicationsLower extremity disabilityTwo-week runFirst clinical trialVA healthcare systemOA painEligible subjectsSecondary outcomesPrimary outcomeGlobal ImpressionNSAID toxicityNoninferiority marginClinical trialsExtremity disabilityCommon causePsychopharmacology Prescribing Workshops: A Novel Method for Teaching Psychiatry Residents How to Talk to Patients About Medications
Kavanagh EP, Cahill J, Arbuckle MR, Lenet AE, Subramanyam K, Winchel RM, Nossel I, DeSilva R, Caravella RA, Ackerman M, Park HC, Ross DA. Psychopharmacology Prescribing Workshops: A Novel Method for Teaching Psychiatry Residents How to Talk to Patients About Medications. Academic Psychiatry 2017, 41: 491-496. PMID: 28194682, DOI: 10.1007/s40596-017-0662-z.Peer-Reviewed Original ResearchConceptsTwo-institutionClasses of medicationsSubset of residentsThird-year psychiatry residentsMedicationsClinical experiencePsychiatry residentsFacilitated group discussionPrescribing skillsInformed consentPatientsResultsThe courseSelf-assessment measuresResident comfortPost surveyCourseResidentsExperienced faculty membersPrescribingGroup discussions
2011
Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence
Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. The American Journal Of Drug And Alcohol Abuse 2011, 37: 1-11. PMID: 21247284, DOI: 10.3109/00952990.2010.540279.Peer-Reviewed Original ResearchConceptsPharmacokinetic drug interactionsDrug interactionsOpioid dependencePsychotropic medicationsPsychoactive medicationsImportant pharmacokinetic drug interactionsClasses of medicationsOpioid-dependent patientsRelevant English-language articlesClinical case seriesMedication-Assisted TreatmentCytochrome P450 isoenzymesImportant clinical consequencesEnglish-language articlesPharmacokinetic interaction studyCase seriesPsychiatric comorbidityEmbase databasesClinical consequencesMedicationsP450 isoenzymesBuprenorphineMethadoneLanguage articlesPsychoactive drugs
2005
Testing an APA Practice Guideline: SymptomTargeted Medication Utilization for Patients With Borderline Personality Disorder
Oldham J, Bender D, Skodol A, Dyck I, Sanislow C, Yen S, Grilo C, Shea M, Zanarini M, Gunderson J, McGlashan T. Testing an APA Practice Guideline: SymptomTargeted Medication Utilization for Patients With Borderline Personality Disorder. FOCUS The Journal Of Lifelong Learning In Psychiatry 2005, 3: 484-488. DOI: 10.1176/foc.3.3.484.Peer-Reviewed Original ResearchBorderline personality disorderMedication utilizationPractice guidelinesPersonality disorderAmerican Psychiatric Association's Practice GuidelineImpulsive-behavioral dyscontrolPsychotropic medication treatmentClasses of medicationsTreatment of patientsComorbid Axis I conditionsAPA practice guidelinesAxis I conditionsAnticonvulsant useMedication treatmentCognitive-perceptual symptomsFunctional impairmentMedication practicesBPD patientsPatientsBPD symptomsSymptomsAffective dysregulationDisordersFunctioning variablesTreatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply